MedinCell S.A. (MEDCL.PA)
EUR 16.8
(5.53%)
EUR 16.8
(5.53%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 58.96 Million EUR | 2.17% |
| 2022 | 57.7 Million EUR | 21.51% |
| 2021 | 47.49 Million EUR | 9.57% |
| 2020 | 43.34 Million EUR | 28.11% |
| 2019 | 33.83 Million EUR | 25.15% |
| 2018 | 27.03 Million EUR | -12.78% |
| 2017 | 30.99 Million EUR | 49.71% |
| 2016 | 20.7 Million EUR | 379.06% |
| 2015 | 4.32 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q2 | 63.2 Million EUR | 0.0% |
| 2023 Q4 | 58.96 Million EUR | 0.0% |
| 2023 FY | 58.96 Million EUR | 2.17% |
| 2022 FY | 57.7 Million EUR | 21.51% |
| 2022 Q4 | 57.7 Million EUR | 0.0% |
| 2022 Q2 | 48.46 Million EUR | 0.0% |
| 2021 FY | 47.49 Million EUR | 9.57% |
| 2021 Q2 | 45.09 Million EUR | 0.0% |
| 2021 Q4 | 47.49 Million EUR | 0.0% |
| 2020 Q2 | 43.96 Million EUR | 0.0% |
| 2020 Q4 | 43.34 Million EUR | 0.0% |
| 2020 FY | 43.34 Million EUR | 28.11% |
| 2019 FY | 33.83 Million EUR | 25.15% |
| 2019 Q2 | 32.78 Million EUR | 0.0% |
| 2019 Q4 | 33.83 Million EUR | 0.0% |
| 2018 Q4 | 27.03 Million EUR | 0.0% |
| 2018 FY | 27.03 Million EUR | -12.78% |
| 2018 Q3 | - EUR | -100.0% |
| 2018 Q2 | 43.99 Million EUR | 0.0% |
| 2018 Q1 | - EUR | -100.0% |
| 2017 Q1 | - EUR | 0.0% |
| 2017 Q3 | - EUR | 0.0% |
| 2017 Q4 | 30.99 Million EUR | 0.0% |
| 2017 FY | 30.99 Million EUR | 49.71% |
| 2016 FY | 20.7 Million EUR | 379.06% |
| 2015 FY | 4.32 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -1639.263% |
| ABIVAX Société Anonyme | 55.46 Million EUR | -6.305% |
| Adocia SA | 13.08 Million EUR | -350.497% |
| Aelis Farma SA | 4.03 Million EUR | -1360.154% |
| Biophytis S.A. | 8.27 Million EUR | -612.95% |
| Advicenne S.A. | 17.42 Million EUR | -238.37% |
| genOway Société anonyme | 7.23 Million EUR | -715.121% |
| IntegraGen SA | 1.12 Million EUR | -5142.213% |
| Medesis Pharma S.A. | 1.2 Million EUR | -4813.417% |
| Neovacs S.A. | 650 Thousand EUR | -8970.923% |
| NFL Biosciences SA | 62.17 Thousand EUR | -94732.245% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1253.4% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -2070.206% |
| Sensorion SA | 2.86 Million EUR | -1955.259% |
| Theranexus Société Anonyme | 3.64 Million EUR | -1518.464% |
| TME Pharma N.V. | 1.16 Million EUR | -4956.69% |
| Valbiotis SA | 6.87 Million EUR | -757.24% |
| TheraVet SA | 1.15 Million EUR | -4983.428% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -555.268% |
| argenx SE | 18.1 Million EUR | -225.656% |
| BioSenic S.A. | 28.16 Million EUR | -109.371% |
| Celyad Oncology SA | 902 Thousand EUR | -6436.696% |
| DBV Technologies S.A. | 13.01 Million USD | -352.898% |
| Galapagos NV | 9.59 Million EUR | -514.433% |
| Genfit S.A. | 70.17 Million EUR | 15.984% |
| GeNeuro SA | 7.73 Million EUR | -661.987% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -1013.733% |
| Innate Pharma S.A. | 39.89 Million EUR | -47.798% |
| Inventiva S.A. | 37.4 Million EUR | -57.62% |
| MaaT Pharma SA | 14.07 Million EUR | -318.906% |
| Nanobiotix S.A. | 50.56 Million EUR | -16.604% |
| Onward Medical N.V. | 16.87 Million EUR | -249.419% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -330.773% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -28.733% |
| Oxurion NV | 12.33 Million EUR | -378.036% |
| Pharming Group N.V. | 155.29 Million EUR | 62.033% |
| Poxel S.A. | 46.9 Million EUR | -25.716% |
| GenSight Biologics S.A. | 18.42 Million EUR | -219.953% |
| Transgene SA | 1.25 Million EUR | -4590.613% |
| Financière de Tubize SA | 79.2 Million EUR | 25.554% |
| UCB SA | 3.03 Billion EUR | 98.059% |
| Valneva SE | 208.81 Million EUR | 71.764% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -155060.526% |